The Q3 beat and reaffirmed guidance are positive but largely in line with the strong growth trajectory. Key catalysts to watch: the Summit Therapeutics collaboration and ivonescimab data, the RSG restructuring execution, and the outcome of the Syntimmune appeal. The $392M judgment is material but appealable and within cash resources.
Price Chart
Executive Summary
AstraZeneca reported Q3 2026 total revenue of $16.21B, up 7% YoY, and Core EPS of $2.79, up 17% YoY, driven by double-digit growth in Oncology, R&I and Rare Disease. The company reconfirmed FY 2026 guidance for mid-to-high single-digit revenue growth and low double-digit Core EPS growth. A $2B equity investment in Summit Therapeutics and a $392M final judgment in the Syntimmune milestone litigation were notable post-period events.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $16.21B, up 7% YoY (CER 7%)
- Q3 2026 Core EPS $2.79, up 17% YoY (CER 19%)
- Q3 2026 Reported EPS $2.02, up 23% YoY (CER 26%)
- FY 2026 guidance reconfirmed: mid-to-high single-digit revenue growth, low double-digit Core EPS growth
- Oncology revenue up 17% YoY (CER) to $7.77B in Q3
- CVRM revenue down 19% YoY (actual) to $2.60B, driven by Farxiga LOE and China VBP
- Rare Disease revenue up 9% YoY (actual) to $2.63B
- Completed $2B equity investment in Summit Therapeutics (12% stake) in October 2026
- Initiated Reshaping for Sustainable Growth programme with up to $2B in restructuring costs and $1.5B in annualised savings
- Syntimmune milestone litigation: $392M final judgment entered against AstraZeneca in October 2026; appeal planned
- Net debt increased $2.46B YTD to $25.83B
- Dividend increased to $3.30 per share for FY 2026
Financial Impact
Q3 revenue $16.21B vs consensus $16.00B; Core EPS $2.79 vs consensus $2.60 (per Street-EPS reference). Revenue beat by ~1.3%, EPS beat by ~7.3%.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Oncology | $7.8B | +17.0% |
| Cardiovascular, Renal & Metabolism | $2.6B | -18.0% |
| Respiratory & Immunology | $2.5B | +11.0% |
| Infectious Disease | $423.0M | +2.0% |
| Rare Disease | $2.6B | +9.0% |
| Other Medicines | $231.0M | -5.0% |
Risk Factors
- Farxiga and Brilinta LOE continue to pressure CVRM revenue (down 19% in Q3)
- Syntimmune $392M judgment plus post-judgment interest; appeal outcome uncertain
- RSG restructuring costs up to $2B may pressure near-term margins
- China VBP and generic competition affecting Lynparza, roxadustat and other products
- Net debt increased to $25.8B; higher interest expense from new borrowings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-009256 |
| Document: 0001654954-26-009256-index-headers.html | 0001654954-26-009256 |
| Document: 0001654954-26-009256-index.html | 0001654954-26-009256 |
| Document: 0001654954-26-009256.txt | 0001654954-26-009256 |
| Earnings Context (Synthetic; results releases only) | 0001654954-26-009256 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 2d ago | 6-K | $174.40 | awaiting T+1 | awaiting T+1 | $186.65 (+7.02%) |
Oct 27, 2026 5d ago | 6-K | $170.08 $169.51 | ▼ −0.34% | ▼ −0.68% | $186.65 (+9.74%) |
Oct 22, 2026 10d ago | 6-K | $172.57 $171.49 | ▼ −0.63% | ▼ −0.10% | $186.65 (+8.16%) |
Oct 15, 2026 18d ago | Court Ruling | $165.41 $163.95 | ▼ −0.88% | ▼ −1.31% | $186.65 (+12.84%) |
Oct 5, 2026 27d ago | 6-K | $156.53 $158.61 | ▲ +1.33% | ▲ +0.78% | $186.65 (+19.24%) |
Oct 2, 2026 4w ago | 6-K | $156.90 $156.53 | ▼ −0.24% | ▼ −0.91% | $186.65 (+18.96%) |
Oct 2, 2026 4w ago | Court Ruling | $156.53 $158.61 | ▲ +1.33% | ▲ +0.78% | $186.65 (+19.24%) |
Oct 1, 2026 4w ago | 6-K | $157.70 $156.90 | ▼ −0.51% | ▼ −1.25% | $186.65 (+18.36%) |
Oct 1, 2026 4w ago | 6-K | $157.70 $156.90 | ▼ −0.51% | ▼ −1.25% | $186.65 (+18.36%) |
Sep 29, 2026 4w ago | 6-K | $164.21 $161.47 | ▼ −1.67% | ▼ −1.46% | $186.65 (+13.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers